RxDoctor Payments Data

Krishnamoorthy Vivekananthan, MD

Cardiovascular Disease · Houston, TXNPI 1972500932

Payments from drug & device makers

$268,133in general payments, 2019–2025

Across 368 payments — averaging $728.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$232K
  • Alnylam Pharmaceuticals Inc.$19K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$10K
  • Actelion Pharmaceuticals US, Inc.$1K
  • Abbott$940
  • AstraZeneca$728
  • plus $4K from 26 others

What the payments were for

  • Food & beverage$8,27899%
  • Education$1221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$268,133 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$344,626
Medicare patients
578
Services billed
2,005

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban193$188,905
XareltoRivaroxaban71$79,377
BrilintaTicagrelor61$48,619
EntrestoSacubitril/Valsartan31$32,892
Nifedipine ErNifedipine362$12,516
Repatha SureclickEvolocumab14$8,891
Labetalol Hcl148$3,629
Midodrine Hcl26$3,268
Prasugrel Hcl18$3,226
Olmesartan Medoxomil164$2,786
Clonidine13$2,282
Amiodarone Hcl59$2,105
Atorvastatin Calcium236$2,076
Valsartan33$1,771
Metoprolol Succinate106$1,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$223$188,905193 claims
Johnson & JohnsonXarelto$444$79,37771 claims
AstraZenecaBrilinta$728$48,61961 claims
NovartisEntresto$231,749$32,89231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →